With the US joining other countries around the world in demanding definitions and measurements of the value of treatments, the pharma industry faces the challenge of understanding the requireme
Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens.